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Abstract  
 
Coronary microvascular dysfunction combined with maladaptive cardiomyocyte morphology and 
energetics are major contributors to heart failure advancement. Thus, dually enhancing cardiac 
angiogenesis and targeting cardiomyocyte function to slow, or reverse, the development of 
heart failure is a logical step towards improved therapy. We present evidence for the potential to 
repurpose a former anti-cancer Arg-Gly-Asp (RGD)-mimetic pentapeptide, Cilengitide, here 
used at low doses. Cilengitide targets αvβ3 integrin and this protein is upregulated in human 
dilated and ischaemic cardiomyopathies. Treatment of mice after abdominal aortic constriction 
(AAC) surgery with low dose (ldCil) enhances coronary angiogenesis and directly affects 
cardiomyocyte hypertrophy with an associated reduction in disease severity. At a molecular 
level, ldCil treatment has a direct effect on cardiac endothelial cell transcriptomic profiles, with a 
significant enhancement of proangiogenic signalling pathways, corroborating the enhanced 
angiogenic phenotype after ldCil treatment. Moreover, ldCil treatment of AngII-stimulated 
cardiomyocytes significantly restores transcriptomic profiles similar to those found in normal 
human heart. The significance of this finding is enhanced by transcriptional similarities between 
AngII-treated cardiomyocytes and failing human hearts. Taken together, our data provide 
evidence supporting a possible new strategy for improved heart failure treatment using low dose 
RGD-mimetics with relevance to human disease. 
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Introduction 
 
Heart failure affects approximately 26 million people worldwide and is characterised by 
insufficient cardiac function, poor coronary microvascular reactivity and maladaptive 
cardiomyocyte hypertrophy. Despite significant therapeutic advances, none of the current 
treatment strategies provide long-term benefit since the disease is associated with a 5-year 
mortality of almost 50 % [1–11]. Given also that current standard-of-care treatments, such as β-
blockers or diuretics, are generally administered indefinitely, can cause serious side effects and 
do not fully mitigate heart failure-related morbidity and mortality, alternative, disease modulating 
solutions are still required. 
 
Integrins are heterodimeric transmembrane adhesion molecules composed of one α-subunit 
and one β-subunit [12]. Apart from their roles in adhesion, integrins have also been shown to be 
allosteric, thus affecting their signalling capacity. The clinical application of inhibiting integrin 
adhesive functions in vivo has proved to be effective (i.e. the anti-platelet effects of αIIβ3 
integrin antagonists), but targeting the vitronectin receptor, αvβ3-integrin [13, 14], appears to be 
less successful. More recently however, methods to target the signalling functions of integrins 
separate from their adhesive roles have emerged especially for αvβ3-integrin. Interestingly, 
whilst αvβ3-integrin is expressed at low levels in the normal heart, it is upregulated in 
endothelial cells and cardiomyocytes of diseased heart [15, 16]. Indeed, vascular-αvβ3-targeting 
probes have been used to image angiogenic areas in damaged heart tissue because αvβ3 is 
upregulated in angiogenic blood vessels [17–20]. These studies and others have also revealed 
elevated endothelial αvβ3 expression after myocardial infarction [17, 21]. However, targeting 
αvβ3-signalling without affecting its adhesive function to control hypertrophic heart disease has 
not been reported previously.    
 
Cilengitide was developed originally as an anti-angiogenic/anti-cancer cyclic RGD-mimetic 
antagonist of αvβ3 integrin when used at maximally-tolerated doses (5–50 mg/kg) [22-26]. In 
contrast to its antagonistic anti-adhesive and anti-angiogenic effects at these doses, we 
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published that low doses of cilengitide (ldCil, 50 µg/kg in vivo or 2 nM in vitro) enhanced 
pathological angiogenesis with no apparent effects on quiescent vasculature.  Mechanistically, 
ldCil does not act as an αvβ3-integrin antagonist and accordingly does not affect cell adhesion 
or migration, but instead alters αvβ3-signalling to enhance the activation and recycling of the 
major pro-angiogenic receptor VEGF-receptor 2 [27]. We have exploited these features of ldCil 
to improve chemotherapy efficacy in cancer models in vivo by actually increasing tumour blood 
vessel number and directly enhancing chemotherapy delivery and metabolism in malignant cells 
[28].  Taken together, these data support ldCil treatment as a strategy to affect αvβ3-integrin 
signalling without affecting cell adhesion and migration. 
 
Here we provide evidence to rationalise the repurposing of ldCil for the treatment of heart 
failure.  We show that treatment with ldCil in abdominal aortic constriction, a well-established 
mouse model of heart failure, restores cardiac function to near normal levels. Indeed, we 
provide evidence that ldCil treatment enhances cardiac angiogenesis with a correlative increase 
in endothelial cell activation at the transcriptomic level. In complementary studies involving 
comparisons with published Illumina and RNA-Seq data from normal and human heart failure 
we show that angiotensin II treatment of mouse cardiomyocytes induces many of the 
transcriptomic changes observed in human heart failure, and that treatment of angiotensin II 
exposed cardiomyocytes with ldCil restores these transcriptomic changes back towards those 
found in normal human heart transcriptomic profiles. Together, these data indicate that 
repurposing cilengitide may have salutary impact on human heart failure. 
 
Materials and methods  
 
Human heart tissue 
Human myocardial tissue was obtained under protocol ethical regulations approved by 
Institutional Review Boards at the University of Pennsylvania and the Gift-of-Life Donor Program 
(Pennsylvania, USA). Whole hearts and dissected left ventricle cavity were weighed to 
determine levels of hypertrophy. Transmural myocardial samples were dissected from the mid 
left ventricular free wall. Snap frozen tissue samples and formalin fixed paraffin embedded 
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(FFPE) sections were provided. Additional details are provided in supplementary material, 
Supplementary materials and methods. 
 
Western blotting analysis of human heart tissue  
Less than 100 mg snap-frozen tissue was lysed in RIPA buffer supplemented with protease 
inhibitor cocktail (Merck-Sigma, Gillingham, UK). Tissue was homogenised using a Polytron 
tissue homogeniser for 30 s followed by centrifugation, for 15 min at 4 °C, to pellet tissue debris. 
Lysates were subjected to SDS-PAGE and transferred to nitrocellulose membranes (Amersham 
Biosciences, Amersham, UK) for Western blotting. Blots were probed for β3-integrin (Ab a kind 
gift from Barry Coller, Rockefeller University, 1:500), succinate dehydrogenase (ab178423, 
1:1000, Abcam, Cambridge UK), pyruvate dehydrogenase (ab131263, 1:1000, Abcam), 
aconitase, (ab129069, 1:10 000, Abcam) and GAPDH (AB2302, Merck, Hoddeston, UK). 
Densitometric readings of band intensities were obtained using ImageJ software (NIH, USA). 
 
Immunofluorescence for β3-integrin in human heart tissue  
Paraffin embedded tissues were dewaxed, blocked in 10 % normal goat serum, NGS, and 1 % 
bovine serum albumin, BSA, for 1 h, followed by incubation with anti-β3 primary antibody 
(1:200, clone 2C9.G3, 14-0611-85, Fisher Scientific, Loughborough, UK) in blocking buffer (10 
% NGS, 1 % BSA) overnight. Next, sections were incubated for 2 h at room temperature with 
secondary antibody in blocking buffer (10 % NGS, 1 % BSA) conjugated to Alexa Fluor 488 
(1:100, Invitrogen, Loughborough, UK), before being immersed in Sudan Black for 15 min to 
reduce autofluorescence. Sections were washed and mounted in prolong gold with DAPI 
(Invitrogen). Stained sections were imaged on the Zeiss 710 confocal microscope and 
processed using ImageJ software.   
 
Studies in mice 
All procedures were approved by the Animal Welfare and Ethical Review Board (AWERB) at 
Queen Mary University of London and were executed in accordance with UK Home Office 
Animals (Scientific Procedures) Act 1986. 
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Abdominal abdominal aortic constriction (AAC)  
Abdominal AAC is a common experimental procedure used to elicit pressure overload-induced 
heart failure in murine models. AAC provides a time-dependent, reproducible model of HF 
characterised by a significant rise in left ventricular weight, deleterious myocardial dilation, and 
a reduction in cardiac inotropy, and rise in myocardial fibrosis. Physiologically this mimics some 
of the clinical features of human aortic stenosis. In an effort to ensure reproducibility amongst 
AAC surgeries only male mice weighing between 20 and 22 g (correlating to 4–5 weeks of age) 
(Charles River, Harlow, UK) were used. Additional details are provided in supplementary 
material, Supplementary materials and methods..  
 
Cilengitide administration 
Cilengitide (Bachem, Bubendorf, Switzerland) was stored as a 2 M solution in saline at -20 °C 
prior to use, before thawing and serial diluting to an appropriate concentration with sterile saline 
for use. Injections were administered 3 times per week at the indicated doses intraperitoneally 
(IP). Low dose Cilengitide (ldCil) is classified as 50 µg/kg [27]. 
 
Echocardiography  
Cardiac function was assessed by transthoracic echocardiography using a VisualSonics Vevo 
770 30-MHz transduction probe (VisualSonics, Amsterdam, Netherlands). Additional details are 
provided in supplementary material, Supplementary materials and methods. 
 
Mean arterial blood pressure (MABP)  
Blood pressure was recorded in anaesthetised mice via intra-arterial cannulation of a carotid 
artery 6 weeks post-AAC surgery, using a Microtip pressure catheter (Millar instruments, 
Oxford, UK). MABP was then averaged across a 30 s period using MATLAB analysis. Additional 
details are provided in supplementary material, Supplementary materials and methods. 
 
Immunofluorescence for wheatgerm agglutin (WGA) and CD31 and measurement of 
cardiomyocyte size and blood vessel density  
This article is protected by copyright. All rights reserved.
 
  
Immunofluorescence for WGA (W11261, Invitrogen) and endomucin (sc-65495, clone V7C7, 
Santa Cruz, Insight Biotechnology Ltd, Wembley, UK) was performed on 5 µm snap-frozen 
heart sections. Additional details are provided in supplementary material, Supplementary 
materials and methods. 
 
Cardiac endothelial cell isolation  
Primary mouse endothelial cells were isolated from the whole hearts of C57/BL6 3-7day old 
mice as described previously [29].   
 
Cardiomyocyte cell isolation culture 
Primary mouse cardiomyocytes were isolated from the whole hearts of 1-3-day old C57/BL6 
wild-type mice. Additional details are provided in supplementary material, Supplementary 
materials and methods. 
 
Western blot analysis of cardiomyocytes 
Cardiomyocytes were prepared and treated as above. Cells were lysed with RIPA buffer and 20 
µg protein loaded onto 10 % gels. Membranes were probed for succinate dehydrogenase 
(Abcam, ab178423), pyruvate dehydrogenase (Abcam, ab131263), aconitase (Abcam, 
ab129069) and GAPDH (AB2302, 1:5000, Millipore) Densitometric readings of band intensities 
were obtained using ImageJ software. 
 
RNA analysis by RT-qPCR and RNA-Seq  
RNA was extracted from cells using the RNeasy mini kit according to the manufacturer’s 
instructions, (Qiagen UK, Manchester, UK). For whole hearts, less than 100 mg of tissue was 
lysed with RLT lysis buffer (Qiagen) in a QIAshredder (Qiagen) for 10 min. Tissues were 
processed with the RNeasy mini kit. Complementary DNA (cDNA) synthesis was carried out 
using the Applied Biosystems High Capacity cDNA Reverse Transcription (RT) Kit (Thermo 
Fisher Scientific) as per the manufacturer’s instructions; 600 ng of mouse tissue/cells cDNA  
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and 1000ng of human heart tissue cDNA was used for qPCR using sample cDNA (FAM-
tagged), an internal control Gapdh (VIC-tagged) and specific TaqMan probes. qPCR was 
carried out using the TaqMan Universal PCR Master Mix (PE Applied Biosystems, Thermo 
Fisher Scientific) in a 96-well plate. 160 ng of cDNA from each sample was amplified using 
qPCR across 40 cycles. Target mRNA was normalised to Gapdh (HPRT1 if human), and the 
expression level of each gene determined relative to the initial experimental controls using the 2-
ΔΔCT method.  
RNA-Seq analyses and comparison with human heart data 
RNA-Seq was performed by Barts and the London Genome Centre on the Illumina NextSeq 500 
platform. Additional details are provided in supplementary material, Supplementary materials 
and methods. 
 
 
Results  
 
β3-integrin expression is elevated in human dilated and ischaemic cardiomyopathies  
To test the utility of low dose cilengitide, ldCil, in the treatment heart failure we first examined 
the expression of its target, β3-integrin, in human non-failing heart, non-failing hypertrophic 
heart, and dilated- and ischaemic-cardiomyopathies. Western blotting for β3-integrin expression 
in human left ventricular biopsy lysates from separate patients indicated that although there 
were no differences in β3-integrin levels between non-failing and non-failing hypertrophic hearts, 
significantly elevated levels were observed in both human dilated-and ischaemic-
cardiomyopathies when compared with non-failing heart tissue (Figure 1A). Immunostaining for 
β3-integrin showed that β3-integrin was present in human non-failing, dilated and ischaemic 
hearts but less so in non-failing with hypertrophy, corroborating western blotting results (Figure 
1B). Taken together these data suggest that β3-integrin is present in human heart failure tissue 
and thus could provide a possible target for treatment. The pathological features of the human 
tissue were identified by H&E and Masson’s Trichrome staining of the FFPE sections 
(supplementary material, Figure S1). 
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Experimental heart failure in mice 
Abdominal aortic constriction (AAC) surgery in mice recapitulates the salient features of human 
heart failure including pressure overload-induced left ventricular cardiac hypertrophy and 
fibrosis [30, 31] and provides a model to test new therapeutic strategies for the treatment of this 
condition. Previous work has showed that treatment with ldCil was sufficient to enhance 
pathological angiogenesis in cancer models [27]. Thus, we hypothesised that ldCil treatment 
may enhance cardiac angiogenesis and blood flow after AAC surgery, and thereby provide a 
strategy to correct the pathobiology of heart failure.  
 
Cardiac function was measured by fractional shortening (FS %) first in a prevention mode 
experimental trial. Cilengitide, or vehicle alone as a control, was administered to mice 3 times a 
week for 7 weeks immediately after SHAM or AAC surgery. At the experimental endpoint (7 
weeks post-surgery) mice that had undergone AAC surgery and treated with vehicle alone 
showed significantly reduced fractional shortening compared with mice that had SHAM surgery 
with vehicle treatment. Administration of ldCil (50 µg/kg) after SHAM surgery also had no 
significant effect on fractional shortening. In contrast, treatment of mice with ldCil (50 µg/kg) but 
not a higher dose of 500 µg/kg, rescued the effect of AAC surgery and restored fractional 
shortening to that observed in SHAM treated mice (Figure 2A, B). These data suggested that 
treatment of mice immediately after AAC surgery with ldCil, a similar dose to that which 
enhanced pathological angiogenesis in cancer models [27], was sufficient to rescue adverse 
heart failure effects in fractional shortening.  
 
We tested the effect of ldCil in a more clinically-relevant intervention reversal study starting 
treatment three weeks after AAC surgery i.e., after heart failure symptoms were established. 
Three weeks post AAC surgery FS %, and ejection fraction (EF %) were significantly reduced 
while left ventricle systole (LVID) was increased when compared with mice that had undergone 
SHAM surgery (Figure 2C). To test the effect of ldCil treatment, mice underwent either SHAM or 
AAC surgery and three 3 weeks later were treated with either vehicle or ldCil 3 times a week for 
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3 weeks. At the end of treatment, although vehicle treatment had no apparent modifying effects, 
ldCil treatment rescued the effects on endpoint FS %, EF %, and LVID (Figure 2D, E). 
Importantly, these effects were independent of changes in mean arterial blood pressure (MABP) 
(Figure 2E). In addition to these functional features, mice that have undergone AAC surgery 
typically exhibit adverse effects of enhanced cardiac hypertrophy with concomitant increased 
heart:body weight ratios [30, 32].  Wheat germ agglutinin (WGA), binds cell membrane 
glycoproteins, and is used to determine cross-sectional sizes of myocytes as a measure of 
cardiomyocyte hypertrophy [33]. Cardiomyocyte perimeter measurements in WGA stained 
sections of heart from experimental end points were reduced in ldCil treated mice after AAC 
surgery compared with vehicle (Figure 2F). Further, ldCil treatment blunted increases in 
heart:body weight ratios in mice after AAC surgery (Figure 2G). Thus, in this intervention mode 
study ldCil treatment restored cardiac function and structure in the AAC model of heart failure to 
levels observed with SHAM surgery.   
 
To test whether ldCil treatment efficacy was maintained, even after treatment cessation, mice 
were given ldCil or vehicle from weeks 3 to 6 post SHAM or AAC surgery and the effects on 
cardiac contractility assessed up to 12 weeks post-surgery. Results indicated that FS % was not 
significantly altered between 3 and 6 weeks or 6 and 12 weeks post SHAM surgery in either 
vehicle-alone or ldCil treated mice. As expected, fractional shortening was significantly reduced 
in vehicle-treated mice after AAC surgery. This reduction in FS % was sustained up until the 12-
week endpoint, indicating the persistent long-term effects of AAC surgery in mice receiving 
vehicle-alone. In contrast, treatment with ldCil elevated fractional shortening significantly 
between 3 and 6 weeks after AAC surgery. This phenotypic rescue was sustained up until 12 
weeks post-surgery at which point there was no significant difference between ldCil treatment 
that had undergone SHAM or AAC surgery (Figure 2H). Thus, intervention treatment with ldCil 
is sustained after cessation of treatment, is disease modifying and potentially provides an 
advantage over current treatment strategies.  
 
Treatment with low dose cilengitide enhances cardiac angiogenesis in vivo 
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We examined the physiological and molecular changes associated with the effect of ldCil in the 
AAC model. Since heart failure is associated with reduced blood flow to the heart, and we have 
published previously that ldCil can increase blood vessel density in pathological angiogenesis 
[27], we examined cardiac capillary density after AAC surgery.  At 2, 3, and 6 weeks post AAC 
surgery heart sections were immunostained for CD31 antibody to detect blood vessels, and the 
number of blood vessels per field of view was assessed. Capillary density was not affected in 
the heart after AAC (supplementary material, Figure S2). In contrast, ldCil treatment significantly 
enhanced cardiac blood vessel density in mice after AAC surgery but had no significant effect in 
mice that had undergone SHAM surgery (Figure 3A).  Interestingly this dose of 50 µg/kg of 
cilengitide was the same that enhanced tumour angiogenesis in previous studies [27, 28]. The 
data indicate that the elevated cardiac function induced by treatment with ldCil after AAC 
surgery was associated with enhanced cardiac blood vessel density. RNA-Seq analysis, to 
define transcriptomic profiles of mouse cardiac endothelial cells treated with ldCil for 24 and 48 
hours, identified 54 concordantly differentially-expressed genes following 24 h and 48 h of ldCil 
treatment (Figure 3B and supplementary material, Figure S3). Indeed, common differentially-
upregulated genes at both 24 h and 48 h of ldCil treatment included several known or putative 
proangiogenic or cardioprotective regulators such as: Csf2rb [34]; Eln [35]; Nov (encoding a 
known ligand of αvβ3 integrin[36]); Ccl7 (CCL7 known to improve cardiac repair [37]); Mt2 [38]; 
Socs2 [39]; Fgf23 (known to protect against cardiac dysfunction [40]); Slc30a1 [41]; Col6a3 [42]; 
Mt1 [43]; Ggt5 [44] and Adam8 [45]. Furthermore, enrichment analysis of RNA-Seq data, at both 
timepoints, showed significant increases in gene sets involved in mitosis, DNA repair and cell 
cycle; all features of enhanced angiogenesis and the myocardial response to injury/pressure 
overload (Figure 3C).   
 
ldCil treatment restores the transcriptomic profiles in AngII-stimulated model of cardiac 
hypertrophy similar to those found in non-failing human heart 
Previous studies have identified that angiotensin II (AngII) treatment of cardiomyocytes mimics 
many features of hypertrophy observed in heart failure in vivo [46]. The direct effect of ldCil on 
cardiomyocytes was examined: AngII-stimulated cardiomyocytes in culture exhibited a 
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significant increase in cell size, supporting the previously published effects on hypertrophy and 
corroborating the use of AngII-stimulation of cardiomyocytes as a model for hypertrophy 
(supplementary material, Figure S4) [46]. Another key feature of hypertrophy observed in both 
human heart failure and AngII-treated mouse cardiomyocytes is the enrichment of foetal-like 
gene programmes involved in cardiac remodelling [47], including upregulation of hypertrophic 
markers such as Myh7. Importantly, additional treatment with ldCil restored Myh7 levels back to 
untreated levels (supplementary material, Figure S5).  These data not only validated the utility of 
AngII-stimulation of cardiomyocytes as a model for hypertrophy, but also indicated that ldCil has 
a direct effect on cardiomyocytes to restore this feature of hypertrophy. Additionally, RNA-Seq 
transcriptome analysis demonstrated that AngII-stimulation of cardiomyocytes resulted in 
significant differential expression changes in multiple genes (Figure 4 A, B). Some of the most 
significantly differentially expressed genes included the upregulation of LIM domain containing 
preferred translocation partner (Lppos), the haploinsufficiency of which has been published to 
be involved in developmental heart defects [48]; Rasa4, RAS p21 protein activator1 which has 
been shown to regulate cardiac fibroblast activation, although no known function in 
cardiomyocytes has been reported to date [49], and the downregulation of neuroglin 2, Nlgn2, 
polymorphisms which have been shown to be associated with blood pressure changes [50], 
whilst Otub2, that encodes the ovarian tumour domain (OTU)-containing subfamily of de-
ubiquitinating enzymes has been associated with multisystemic human disorders including heart 
failure [51]. Treatment with ldCil restored the statistically significant transcriptomic alterations 
induced by AngII back to control treated cardiomyocyte levels for all candidates shown (Figure 
4A, B). Gene sequence enrichment analysis showed that AngII stimulation induced significant 
differential expression of multiple pathways (FDR q<0.1). Once again, after additional treatment 
with ldCil, these changes were no longer significant (FDR q>0.1) (Figure 4C) suggesting that 
treatment with ldCil rescues the signalling pathway alterations induced by AngII. In particular the 
significant increase in TCA and oxidative stress pathways associated with AngII exposure and 
associated with some forms of heart failure [52] are restored by treatment with ldCil. 
Additionally, PI3K and Akt signalling pathways are the most significantly downregulated after 
AngII exposure and are known to be involved in heart failure responses [53].  Indeed, both 
these pathways are highly expressed after treatment with ldCil (Figure 4C). Taken together, 
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these data further corroborated the notion that the direct effects of ldCil on cardiomyocytes 
could be involved in restoring the pathobiology and molecular effects of hypertrophy. 
 
 
ldCil treatment restores transcriptomic changes associated with non-failure in human 
heart 
Previous work, using RNA isolated from bulk human cardiac samples, identified the 
transcriptomic changes that are significantly regulated in human heart failure [54]. To examine 
the relevance of our findings in mouse tissue to human heart disease we identified concordant 
transcriptomic changes published for human failing heart (ischaemic and /or dilated versus 
human non-failing) versus those in the mouse model of hypertrophy (AngII-stimulated 
cardiomyocytes versus control treated cardiomyocytes). We found 290 orthologous genes 
altered concordantly in mouse cardiomyocytes and human failing versus non-failing heart. A 
subgroup of these genes (13 downregulated and 8 upregulated) were restored to non-failing 
human heart levels after treatment of mice with ldCil (Figure 5A). Furthermore, out of the 163 
differentially regulated pathways in AngII-stimulated mouse cardiomyocytes versus control 
cardiomyocytes, 88 were common with the 238 differentially enriched pathways in human 
dilated heart versus non-failing heart (Figure 5B, supplementary material, Figure S6A). GSEA 
analyses revealed that 4 concordantly upregulated and 8 concordantly downregulated pathways 
in human idiopathic dilated cardiomyopathy versus non-failing heart and mouse AngII-
stimulated cardiomyocytes versus control were restored to non-failing human heart profiles after 
ldCil treatment (Figure 5B heatmap, supplementary material, Figure S6A).  Similarly, out of the 
163 differentially-regulated pathways in AngII-stimulated mouse cardiomyocytes versus control 
cardiomyocytes, 83 were common with the 219 differentially enriched pathways in human 
ischaemic heart versus non-failing heart (Figure 5C, supplementary material, Figure S6B). 
GSEA uncovered that 6 concordant pathways, 1 upregulated and 5 downregulated, in human 
ischaemic heart versus non-failing heart and mouse AngII-stimulated cardiomyocytes versus 
control, were restored after treatment with ldCil (Figure 5C, heatmap, supplementary material, 
Figure S6B). Additionally, some of these concordantly enriched pathways were similar for both 
idiopathic dilated and ischaemic cardiomyopathy including insulin signalling pathways, SCF-Kit 
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signalling, NGF signalling, PI3K signalling and AKT signalling suggesting common mechanistic 
signatures that are relevant to the recovery of both cardiomyopathies. Western blotting analyses 
validated some of the differentially expressed TCA-cycle enzyme at the protein level 
(supplementary material, Figure S7). Taken together, these data provide evidence that 
treatment of AngII-stimulated cardiomyocytes with ldCil generates molecular profiles that are 
associated with human non-failing heart. 
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Discussion  
 
Heart failure is a common feature of the final stages of several cardiovascular diseases (e.g. 
hypertension, myocardial infarction (MI)) with characteristic pathologies of reduced 
microvascular blood flow and cardiomyocyte hypertrophy. Importantly, disease-modifying 
strategies with longer lasting pharmacodynamics are required. 
 
Some studies have implicated β3-integrin as a mediator of cardiac remodelling suggesting that 
signalling downstream of this integrin could be disease modifying [17, 20, 21, 55]. Heart failure 
is associated with poor blood vessel perfusion and thus increasing perfusion could be beneficial.  
Cilengitide is an RGD-mimetic that targets αvβ3-integrin [56–58]. In cancer studies, low, but not 
high, doses of this agent induce vascular promotion in pathological conditions, and can also 
enhance chemosensitivity in malignant cells [27, 28].  
 
We hypothesised that because ldCil can have proangiogenic effects in cancer it may also have 
vascular promoting effects in heart failure models that could exert beneficial disease-modifying 
actions. Here, we show that treatment with ldCil enhances cardiac angiogenesis in the AAC 
model of heart failure and inhibit pathological hypertrophy of cardiomyocytes. Moreover, ldCil 
treatment recapitulates some of the transcriptomic profiles of human non-failing hearts, 
suggesting that this strategy may have relevance to human heart failure treatment. Furthermore, 
we show that β3-integrin expression is enhanced in human dilated and ischaemic 
cardiomyopathies.   
 
Current treatments for heart failure are not disease-modifying when treatment ceases and thus 
their efficacy relies on treatment for life [59]. It is of interest that the effects of ldCil in the AAC 
model of heart failure show potentially long-lasting effects. The reasons why this vascular 
promotion effect inducing a pro-angiogenic transcriptomic profile may be effective compared 
with previous proangiogenic strategies such as protein tyrosine phosphatase 1B (PTP1B) 
inactivation [60, 61] or vascular endothelial growth factor-induced neovascularisation [62] are 
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not known currently.  One possibility is that the endothelial cells lining blood vessels act not only 
as conduits for blood flow but also produce their own set of paracrine factors, namely angiocrine 
factors, that can have effects on development and the repair of surrounding tissue [63]. This is a 
relatively new, but exciting, concept in understanding the role of cardiac angiocrine factors in 
cardiac repair [64]. Recognising that angiocrine biology has been related to integrin mediated 
mechanosensing [65] or signalling downstream of endothelial cell-integrins [66] it is possible 
that angiocrine factor production after ldCil treatment may be of significance.  Although beyond 
the scope of the current study it would be of interest to investigate whether the ldCil-treatment-
induced paracrine factors, identified in this study, also aid in cardiac tissue repair.  We also 
speculate that because ldCil treatment has direct effects on cardiomyocyte function and 
hypertrophy, as well as its proangiogenic effects, the combination of these effects on at least 
two cell types in the heart would provide improved restoration of the pathophysiological features 
of heart failure.  
 
Our in vitro data describe how the effects of ldCil on AngII-stressed cardiomyocytes correlate 
with the published transcriptomic signature of a human normal heart compared with failing heart 
[54]. The common transcriptomic signature suggests that if the in vivo ldCil effects on 
cardiomyocytes are similar to those we discovered in vitro, then ldCil treatment could have a 
restorative effect on cardiomyocyte pathophysiology that may be relevant to human heart 
disease. Limitations of our study include the relatively few, but statistically relevant, mice used in 
the in vivo AAC experiments, together with the fact that AAC is a model of heart failure that 
does not include some of the pathophysiological causes of the disease in humans, such as lack 
of exercise or smoking. Additionally, the expected high mortality rates of mice at 12 weeks post 
AAC surgery limited the design of the longer-term experiments presented. Despite these 
limitations, our data do correlate human heart failure with our observations in mouse models 
providing some confidence in the interpretation of the results. Overall, our results suggest that 
treatment with ldCil merits further investigation for disease modifying effects in heart failure.  
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Figure legends 
 
Figure 1. β3-integrin expression is upregulated in human dilated- and ischaemic-
cardiomyopathy. (A) Western blotting analysis of β3-integrin in protein lysates from human 
non-failing heart, non-failing heart with hypertrophy, dilated- and ischaemic-myocardium. 
GAPDH was used as a loading control.  Bar charts show mean densitometric readings ± SEM. 
N = 5 or 6 individual patient samples.  (B) Immunofluorescence reveals β3-integrin expression in 
sections of human non-failing heart with an apparent increase in dilated- and ischaemic- hearts, 
but less in non-failing heart with hypertrophy. The non-specific primary antibody control showed 
minimal background level staining. N, 4 individual patient samples per group. Scale bar, 50 µm. 
Student’s t-test, *p<0.05.  
 
Figure 2.  Low dose cilengitide treatment restores the effect of pressure overload 
induced by abdominal aortic constriction. (A) Wild type mice underwent either SHAM, or 
abdominal aortic constriction (AAC) surgery and were either treated with cilengitide (Cil, 50 
µg/kg or 500 µg/kg) or vehicle alone immediately after surgery in a preventative mode trial. 
Representative endpoint echocardiographic images in vehicle and Cil treated SHAM-surgery or 
AAC-surgery mice (n, 7 mice per group). Double-headed arrows, LV internal diameter at 
diastole (LVIDd) and systole (LVIDs). (B) Treatment of mice with 50 µg/kg, but not 500 µg/kg, 
cilengitide corrected the fractional shortening effects after AAC surgery. Line graphs show 
summary fractional shortening (FS %) analysis over time, and bar chart the end point FS % 
from the mice treated in (A). (C) Three weeks after AAC surgery both FS % and ejection fraction 
(EF %) were reduced, whilst left ventricular internal diameter (during systole) (LVID;s) was 
enhanced compared with SHAM controls (n, 5 mice per group). (D) Treatment of mice with ldCil 
rescued the fractional shortening effects of AAC surgery in an intervention mode trial. Wild type 
mice underwent either SHAM or AAC surgery and 3 weeks after surgery were treated with 
either vehicle alone or 50 µg/kg Cil (low dose cilengitide, ldCil) 3 times a week for 3 weeks. 
Representative endpoint echocardiographic images in SHAM-surgery or AAC-surgery mice 
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treated with either vehicle or ldCil from week 3 to week 6 post-surgery (n, 7 mice per group). 
Line graphs, summary fractional shortening (FS %) over time. (E) Functional parameters from 
mice in (D): Endpoint FS %, EF % and LVID;s were rescued after ldCil treatment in mice after 
AAC surgery. Mean arterial blood pressure (MABP) was not affected by ldCil treatment (n, 3 
mice per group). (F) Sections of myocardium from mice in (D) stained with fluorescence-labelled 
wheat germ agglutinin to detect cell perimeters. Image analysis of cardiomyocyte perimeter 
indicates that treatment with ldCil was sufficient to rescue the myocyte size defect compared 
with mice with SHAM surgery (n, 3 mice per group). (G) Heart weight normalised to body weight 
across treatment groups (n, 7 mice per group). (H) Treatment with ldCil provided sustained 
recovery after AAC surgery. Wild type mice underwent either SHAM or AAC surgery. From 3–6 
weeks post-surgery mice were either treated with ldCil, or given vehicle alone as control and 
fractional shortening was measured at 0, 3, 6, and 12 weeks post-surgery. Line graphs, 
summary FS % over time. At 3 weeks post-AAC surgery FS % was significantly reduced in mice 
after AAC surgery and this effect did not recover in mice given vehicle alone.  In contrast, mice 
treated with ldCil from 3-6 weeks post AAC surgery showed recovery in FS % that was 
sustained for 6 weeks after treatment cessation (n, 3–6 mice per group). Mean ± SEM. 
Statistical analysis (B–G) 1-way ANOVA with Tukey’s post hoc analysis. Statistical analysis in 
(H) non-parametric test Mann–Whitney. *p<0.05, **p<0.01. NS, not significant. Scale bar in (F) 
20 µm.   
 
Figure 3. Treatment with low dose cilengitide enhances cardiac blood vessel density in 
vivo and stimulates cardiac endothelial cell DNA-replication, mitosis and cell-cycle 
transition transcriptional profiles. (A) Wild type mice underwent either SHAM or AAC surgery 
and were treated with ldCil or vehicle control for 3 weeks. Representative immunofluorescence 
images of myocardium stained for the endothelial cell marker CD31. Treatment with ldCil 
enhanced blood vessel density (BVD) in the myocardium of mice after AAC but not SHAM 
surgery. Mean ± SEM. 1-way ANOVA with Tukey’s post hoc test; *p<0.05. NS, not significant. 
(B) Duplicate preparations of mouse cardiac endothelial cells were treated for 0, 24 or 48 h with 
ldCil and RNA-Seq performed. Heatmap of differentially expressed (DE) up- and down-
regulated transcripts in cardiac endothelial cells treated with ldCil.  Results are shown for 
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duplicate samples. 54 DE genes were concordant at 24 h and 48 h ldCil treatment compared 
with control. (C) Enrichment analysis of RNA-Seq data demonstrates that treatment of cardiac 
endothelial cells significantly enriches for cell cycle, DNA replication, cell cycle, mitosis, and 
DNA strand elongation pathways; all involved in cell proliferation, a key process in 
angiogenesis.  
 
Figure 4.  Low dose cilengitide treatment reverses the transcriptomic profiles of AngII-
stimulated cardiomyocytes to control levels. (A) Mouse cardiomyocytes were isolated and 
either exposed to angiotensin II (AngII) to mimic the molecular stress of heart failure or exposed 
to AngII and also treated with ldCil. Heat map of differentially expressed protein coding genes 
indicates that AngII-stimulation resulted in 13 down- and 9 up-regulated transcripts. ldCil 
treatment of AngII-stimulated cardiomyocytes rescues the differentially-expressed (DE) 
transcript profiles. (B) Data from (A) represented in order of fold-change. DE protein-coding 
genes with **p<0.01 in AngII versus control, also with high average expression across samples, 
became not DE (p>0.05) in AngII + ldCil group compared to control. Green bars show levels of 
fold-change. (C) Treatment with ldCil restores aberrant signalling pathways induced by AngII-
stimulation of cardiomyocytes. GSEA of KEGG and reactome signalling pathways reveal that 
dysregulated pathways with FDR q<0.1 in AngII versus control, became not significant (q>0.1) 
in AngII + ldCil compared to control.  
 
Figure 5.  Low dose cilengitide treatment restores transcriptomic profiles in mouse 
cardiomyocytes similar to those found in non-failing human heart. (A) Treatment of mouse 
cardiomyocytes with AngII + ldCil compared with AngII restores transcriptomic signature similar 
to that found in human non-failing vs failing heart. Heatmap illustrates concordant DE transcripts 
between human failing (ischaemic- and dilated-cardiomyopathies) versus non-failing heart and 
mouse cardiomyocytes treated with AngII versus Control or AngII versus AngII + ldCil. (B) Venn 
diagrams show the overlap of gene sequence expression analysis (GSEA) pathways (p < 0.05) 
in mouse cardiomyocytes stimulated with AngII versus control and human dilated 
cardiomyopathy (CMP) versus non-failing heart. Scatterplots of Normalised Enrichment Scores 
(NES) of the overlapping pathways illustrate how many of those change concordantly. Heatmap 
This article is protected by copyright. All rights reserved.
 
  
of NES for GSEA pathways that change concordantly in human dilated CMP versus non-failing 
heart, mouse AngII-stimulated versus control cardiomyocytes and AngII-stimulated 
cardiomyocytes treated with ldCil versus AngII-stimulated cardiomyocytes. (C) Venn diagrams 
of the overlap of GSEA pathways (p < 0.05) in mouse cardiomyocytes stimulated with AngII 
versus mouse control and human ischaemic CMP versus non-failing heart.  Scatterplots of NES 
of the overlapping pathways illustrate how many of those change concordantly. Heatmap of 
NES for GSEA pathways that change concordantly in human ischaemic versus human non-
failing heart, mouse AngII-stimulated versus control mouse cardiomyocytes and AngII-
stimulated mouse cardiomyocytes treated with ldCil versus AngII-stimulated mouse 
cardiomyocytes.  
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